Alterity Therapeutics (HAM:PBN) Shares Outstanding (EOP): 217.51 Mil (As of Dec. 2025)


HAM:PBN Alterity Therapeutics Ltd HAM:PBN
34 GF Score
Price €0.38
View Full Analysis

What is Alterity Therapeutics Shares Outstanding (EOP)?

Alterity Therapeutics HAM:PBN +15.06% 34 Shares Outstanding (EOP) is 217.51 Mil as of Dec. 2025. GuruFocus rates HAM:PBN with a GF Score™ of 34/100.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Alterity Therapeutics's shares outstanding for the quarter that ended in Dec. 2025 was 217.51 Mil.

Alterity Therapeutics's quarterly shares outstanding stayed the same from Sep. 2025 (217.51 Mil) to Dec. 2025 (217.51 Mil).

Alterity Therapeutics's annual shares outstanding increased from Jun. 2024 (104.90 Mil) to Jun. 2025 (182.55 Mil). It means Alterity Therapeutics issued new shares from Jun. 2024 to Jun. 2025 .


Alterity Therapeutics  (HAM:PBN) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Alterity Therapeutics Shares Outstanding (EOP) Related Terms


Alterity Therapeutics Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Alterity Therapeutics's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alterity Therapeutics Shares Outstanding (EOP) Chart

Alterity Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.68 48.14 48.80 104.90 182.55

Alterity Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 177.64 182.55 217.51 217.51 217.51

HAM:PBN vs VRTX, REGN, ALNY: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Alterity Therapeutics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alterity Therapeutics Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alterity Therapeutics's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Alterity Therapeutics's Shares Outstanding (EOP) falls into.


HAM:PBN
34GF Score
Alterity Therapeutics Ltd HAM:PBN
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alterity Therapeutics Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 217.51 Mil mean?
Alterity Therapeutics (HAM:PBN) has a Shares Outstanding (EOP) of 217.51 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on Alterity Therapeutics and its competitors.
Is Alterity Therapeutics' Shares Outstanding (EOP) too high?
Alterity Therapeutics' current Shares Outstanding (EOP) is 217.51 Mil. Overall, Alterity Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Alterity Therapeutics' Shares Outstanding (EOP) compare to VRTX and REGN?
Alterity Therapeutics' Shares Outstanding (EOP) of 217.51 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Alterity Therapeutics and its competitors. Alterity Therapeutics's current Shares Outstanding (EOP) is 217.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alterity Therapeutics stock overvalued right now?
Alterity Therapeutics (HAM:PBN) has a current Shares Outstanding (EOP) of 217.51 Mil. The current Shares Outstanding (EOP) is 217.51 Mil. Alterity Therapeutics' overall GF Score™ is 34/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Alterity Therapeutics (HAM:PBN), the current Shares Outstanding (EOP) is 217.51 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alterity Therapeutics Business Description

Address 350 Collins Street, Suite 4, Level 14, Melbourne, VIC, AUS, 3000
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
34GF Score

Get the complete analysis for HAM:PBN

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.38
Price